Advertisement
U.S. Markets open in 49 mins

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
4.9500-0.0800 (-1.59%)
At close: 04:00PM EDT
4.8816 -0.07 (-1.38%)
After hours: 07:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close5.0300
Open4.9500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.6900 - 5.0050
52 Week Range1.3600 - 6.2300
Volume1,434,750
Avg. Volume1,278,328
Market Cap450.746M
Beta (5Y Monthly)2.84
PE Ratio (TTM)N/A
EPS (TTM)-0.3600
Earnings DateNov 04, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.44
  • GlobeNewswire

    Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

    WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the third quarter ended September 30, 2024 and provide an update on recent developments in its business after market close on Monday, November 4, 2024. Management will host a con

  • Benzinga

    Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate

    On Friday, Aquestive Therapeutics, Inc. (NASDAQ:AQST) hosted a virtual investor day highlighting the company’s Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel. Aquestive said it completed enrollment in its remaining supportive study for Anaphylm, the oral allergy syndrome (OAS) challenge study. Following the completion of dosing, the study is expected to be completed in the fourth quarter of 2024. The company remains on track to hold the FDA pre-New Drug Application